Zydus Lifesciences has officially announced the completion of its acquisition of the API Business of Sterling Biotech Limited. This development follows the fulfillment of all conditions precedent and closing date adjustments as stipulated in the Business Transfer Agreement. The integration of this API business is a key strategic step for Zydus Lifesciences, aiming to bolster its capabilities and market presence in the pharmaceutical ingredients sector.
Zydus Lifesciences Finalizes API Business Acquisition
Zydus Lifesciences Limited announced on November 2, 2026, the successful completion of its acquisition of the API Business from Sterling Biotech Limited. This significant milestone was achieved after all prerequisites and adjustments outlined in the Business Transfer Agreement, dated September 17, 2024, were met.
Strategic Integration of API Assets
The acquisition represents a crucial strategic advancement for Zydus Lifesciences, aimed at enhancing its vertical integration and expanding its presence in the Active Pharmaceutical Ingredients (API) market. The company has informed stakeholders that the integration process is now complete, marking a new phase in its operational strategy.
Official Confirmation and Record
The company has requested that this information be taken on record by all relevant parties. The formal announcement was made by Dhaval N. Soni, Company Secretary and Compliance Officer of Zydus Lifesciences Limited.
Source: BSE
